AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8640072 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intravenous thymopentin (TP5) treatment
Number of subjects: 8
Study 1597660 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium bifidum and Lactobacillus acidophilus (Infloran) administered in capsules (two capsules 4 times per day) for 28 days
Number of subjects: 15
Study 1597660 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered in the same posology for 28 days
Number of subjects: 15
Study 2996156 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose corticotrophin (ACTH)
Number of subjects: 14
Study 2996156 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 29255011 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard NAS pack
Number of subjects: 909
Study 29255011 — intervention group
Group type: COMPARATOR
Intervention: Plain packaging
Number of subjects: 909
Study 29255011 — intervention group
Group type: COMPARATOR
Intervention: Australian-like packaging
Number of subjects: 909
Study 28770596 — intervention group
Group type: EXPERIMENTAL
Intervention: Streamlined care model (ART: efavirenz [EFV]/tenofovir disoproxil fumarate + emtricitabine (FTC) or lamivudine (3TC))
Number of subjects: 972
Study 24803495 — intervention group
Group type: EXPERIMENTAL
Intervention: Active somatosensory stimulation (SS)
Number of subjects: 33
Study 24803495 — intervention group
Group type: COMPARATOR
Intervention: Sham somatosensory stimulation (SS)
Number of subjects: 33
Study 23129742 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy with docetaxel, cisplatin, and fluorouracil (TPF) followed by surgery and postoperative radiotherapy
Number of subjects: 256
Study 23129742 — intervention group
Group type: COMPARATOR
Intervention: Up-front surgery and postoperative radiotherapy
Number of subjects: 256
Study 21999189 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-dose group (40 mg/Kg TA before and after CPB)
Number of subjects: 160
Study 21999189 — intervention group
Group type: COMPARATOR
Intervention: Single-dose group (40 mg/Kg TA before CPB and placebo after CPB)
Number of subjects: 160
Study 21999189 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-dose group (TA2)
Number of subjects: 160
Study 21999189 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-dose group
Number of subjects: 160
Study 21999189 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 160
Study 18192495 — intervention group
Group type: EXPERIMENTAL
Intervention: True iontophoresis (TI) with a 40‐mA/min dose of iontophoresis using a 0.4% (4 mg/mL) solution of dexamethasone
Number of subjects: 29
Study 18192495 — intervention group
Group type: COMPARATOR
Intervention: Sham iontophoresis (SI)
Number of subjects: 29
Study 18192495 — intervention group
Group type: COMPARATOR
Intervention: Control samples
Number of subjects: 29
Study 16369107 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month intervention
Number of subjects: 33
Study 16369107 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month intervention
Number of subjects: 33
Study 14666759 — intervention group
Group type: EXPERIMENTAL
Intervention: Nuzhen Yangyin Granule (NYG)
Number of subjects: 30
Study 14666759 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 10728173 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine (75 mg/day) plus CBT
Number of subjects: 24
Study 10728173 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine (40 mg/day) plus CBT
Number of subjects: 24
Study 8554391 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen (150 mg IM)
Number of subjects: 135
Study 8554391 — intervention group
Group type: COMPARATOR
Intervention: Dipyrone (2 gm) + Hyoscine N-butylbromide (20 mg)
Number of subjects: 135
Study 1952859 — intervention group
Group type: EXPERIMENTAL
Intervention: Furazolidone at 7 mg/kg/day once
Number of subjects: 118
Study 1952859 — intervention group
Group type: EXPERIMENTAL
Intervention: Furazolidone at 7 mg/kg/day divided into four doses for 3 days
Number of subjects: 118
Study 1952859 — intervention group
Group type: COMPARATOR
Intervention: Placebo once
Number of subjects: 118
Study 1952859 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 3 days
Number of subjects: 118
Study 7037012 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclobrate (100 mg twice daily)
Number of subjects: 19
Study 7037012 — intervention group
Group type: EXPERIMENTAL
Intervention: Eniclobrate (130 mg twice daily)
Number of subjects: 19
Study 7037012 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 31504390 — intervention group
Group type: EXPERIMENTAL
Intervention: Detailed verbal instructions on orthodontic pain and a take-home information leaflet
Number of subjects: 60
Study 31504390 — intervention group
Group type: COMPARATOR
Intervention: General verbal information on orthodontic treatment
Number of subjects: 60
Study 31732214 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib
Number of subjects: 28
Study 28649035 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted intervention including outreach visits and morbidity/mortality conferences (MMC)
Number of subjects: 165353
Study 28649035 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention)
Number of subjects: 165353
Study 24725729 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-load/high-repetition elastic band resistance training (RT) for 8 weeks, three sessions per week, combined with patient education (four occasions)
Number of subjects: 44
Study 24725729 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving patient education alone
Number of subjects: 44
Study 24725729 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-load/high-repetition elastic band resistance training (RT)
Number of subjects: 44
Study 24369114 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 Gy in a single fraction
Number of subjects: 425
Study 24369114 — intervention group
Group type: COMPARATOR
Intervention: 20 Gy in multiple fractions
Number of subjects: 425
Study 22951488 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily controls with CBCT
Number of subjects: 241
Study 22951488 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily controls with fiducial markers
Number of subjects: 241
Study 22951488 — intervention group
Group type: COMPARATOR
Intervention: Weekly controls with CBCT
Number of subjects: 241
Study 22951488 — intervention group
Group type: COMPARATOR
Intervention: Weekly controls with fiducial markers
Number of subjects: 241
Study 22951488 — intervention group
Group type: COMPARATOR
Intervention: Daily controls compared to PI with CBCT
Number of subjects: 241
Study 22951488 — intervention group
Group type: COMPARATOR
Intervention: Daily controls compared to PI with fiducial markers
Number of subjects: 241
Study 19652059 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomalidomide (2 mg/d) plus placebo
Number of subjects: 84
Study 19652059 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomalidomide (2 mg/d) plus prednisone
Number of subjects: 84
Study 19652059 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomalidomide (0.5 mg/d) plus prednisone
Number of subjects: 84
Study 19652059 — intervention group
Group type: COMPARATOR
Intervention: Prednisone plus placebo
Number of subjects: 84
Study 19652059 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomalidomide (2 mg/d) plus placebo (n = 62 patients receiving > or = 3 cycles)
Number of subjects: 84
Study 19652059 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomalidomide (2 mg/d) plus prednisone (n = 62 patients receiving > or = 3 cycles)
Number of subjects: 84
Study 19652059 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomalidomide (0.5 mg/d) plus prednisone (n = 62 patients receiving > or = 3 cycles)
Number of subjects: 84
Study 19652059 — intervention group
Group type: COMPARATOR
Intervention: Prednisone plus placebo (n = 62 patients receiving > or = 3 cycles)
Number of subjects: 84
Study 19652059 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomalidomide therapy (0.5 or 2 mg/d) with or without prednisone
Number of subjects: 84
Study 19652059 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment arms
Number of subjects: 84
Study 18261356 — intervention group
Group type: EXPERIMENTAL
Intervention: MCAS group (based on TCD examination)
Number of subjects: 1068
Study 18261356 — intervention group
Group type: EXPERIMENTAL
Intervention: MCAS group
Number of subjects: 1068
Study 18261356 — intervention group
Group type: COMPARATOR
Intervention: non-MCAS group
Number of subjects: 1068
Study 14712348 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% dextrose (study iii)
Number of subjects: 8
Study 14712348 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralipid and heparin (study ii)
Number of subjects: 8
Study 14712348 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralipid and heparin combined with 20% dextrose (study iv)
Number of subjects: 8
Study 14712348 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (study i)
Number of subjects: 8
Study 11165419 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based recruitment
Number of subjects: 0
Study 11165419 — intervention group
Group type: COMPARATOR
Intervention: Hospital-based recruitment
Number of subjects: 0
Study 11165419 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall screening and recruitment
Number of subjects: 0
Study 10730110 — intervention group
Group type: EXPERIMENTAL
Intervention: 330 mL beer (containing about 20 g ethanol)
Number of subjects: 52
Study 9135531 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral dietary supplements during inpatient phase
Number of subjects: 100
Study 9135531 — intervention group
Group type: COMPARATOR
Intervention: Control (normal ward diet) during inpatient phase
Number of subjects: 100
Study 9135531 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral dietary supplements during outpatient phase
Number of subjects: 100
Study 1901332 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant interferon-gamma (rIFN-gamma) therapy
Number of subjects: 0
Study 1901332 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7041652 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoxitin (3 doses of 2 gm each)
Number of subjects: 266
Study 7041652 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 266
Study 31933417 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary cytoreduction surgery (SCS)
Number of subjects: 62
Study 31050066 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein supplementation pre-exercise (WP-PLA)
Number of subjects: 70
Study 31050066 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein supplementation post-exercise (PLA-WP)
Number of subjects: 70
Study 31050066 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA-PLA)
Number of subjects: 70
Study 28524243 — intervention group
Group type: EXPERIMENTAL
Intervention: Flowable resin composite (SDR) in bulk increments of up to 4 mm
Number of subjects: 38
Study 28524243 — intervention group
Group type: COMPARATOR
Intervention: Conventional 2-mm resin composite layering technique
Number of subjects: 38
Study 25824424 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram, Sertraline, Venlafaxine-XR (SSRIs and SNRIs)
Number of subjects: 80
Study 25824424 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine-XR
Number of subjects: 80
Study 25824424 — intervention group
Group type: COMPARATOR
Intervention: Non-responders to Venlafaxine-XR
Number of subjects: 80
Study 25824424 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 80
Study 23160149 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovenous laser ablation (EVLA)
Number of subjects: 106
Study 23160149 — intervention group
Group type: COMPARATOR
Intervention: Conventional surgery
Number of subjects: 106
Study 22008366 — intervention group
Group type: EXPERIMENTAL
Intervention: Community health centres (salary-based physicians)
Number of subjects: 4808
Study 22008366 — intervention group
Group type: EXPERIMENTAL
Intervention: Blended capitation practices
Number of subjects: 4808
Study 22008366 — intervention group
Group type: COMPARATOR
Intervention: Fee-for-service practices
Number of subjects: 4808
Study 18450847 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based kangaroo mother care
Number of subjects: 4165
Study 18450847 — intervention group
Group type: COMPARATOR
Intervention: Control group (no community-based kangaroo mother care)
Number of subjects: 4165
Study 17048428 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose oral vitamin B6 (50 mg), vitamin B12 (1 mg), and folic acid (15 mg) daily for 6 months
Number of subjects: 54
Study 17048428 — intervention group
Group type: COMPARATOR
Intervention: Oral 5 mg folic acid alone for 6 months
Number of subjects: 54
Study 17048428 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose oral vitamin B6, vitamin B12, and folic acid
Number of subjects: 54
Study 12612510 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic hemoclip placement
Number of subjects: 79
Study 12612510 — intervention group
Group type: COMPARATOR
Intervention: Distilled water injection
Number of subjects: 79
Study 10984820 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 8689841 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-induced hypoglycaemia (blood glucose 2.5 ± 0.4 mmol l-1 for 62 ± 8 min)
Number of subjects: 10
Study 8689841 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-induced hypoglycaemia
Number of subjects: 10
Study 2062511 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (650 mg per day)
Number of subjects: 3711
Study 2062511 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3711
Study 6660476 — intervention group
Group type: EXPERIMENTAL
Intervention: diazepam 10 mg/70 kg
Number of subjects: 28
Study 6660476 — intervention group
Group type: EXPERIMENTAL
Intervention: flunitrazepam 1 mg/70 kg
Number of subjects: 28
Study 6660476 — intervention group
Group type: EXPERIMENTAL
Intervention: fentanyl 0.15 mg/70 kg
Number of subjects: 28
Study 6660476 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 28
Study 30785358 — intervention group
Group type: EXPERIMENTAL
Intervention: Alemtuzumab 12 mg
Number of subjects: 1485
Study 30785358 — intervention group
Group type: EXPERIMENTAL
Intervention: Alemtuzumab 24 mg
Number of subjects: 1485
Study 30785358 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous interferon beta‐1a (control)
Number of subjects: 1485
Study 29741714 — intervention group
Group type: EXPERIMENTAL
Intervention: Enriching early-life activities score
Number of subjects: 93
Study 29148881 — intervention group
Group type: EXPERIMENTAL
Intervention: 32 mg of buprenorphine
Number of subjects: 40
Study 29148881 — intervention group
Group type: EXPERIMENTAL
Intervention: 64 mg of buprenorphine
Number of subjects: 40
Study 29148881 — intervention group
Group type: EXPERIMENTAL
Intervention: 96 mg of buprenorphine
Number of subjects: 40
Study 29148881 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 40
Study 26422298 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of solifenacin 5 mg and mirabegron 25 mg
Number of subjects: 0
Study 26422298 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of solifenacin 5 mg and mirabegron 50 mg
Number of subjects: 0
Study 26422298 — intervention group
Group type: COMPARATOR
Intervention: Monotherapies (solifenacin and mirabegron)
Number of subjects: 0
Study 23765449 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive Voice Response System (IVRS) version of the EORTC QLQ-C30
Number of subjects: 0
Study 23765449 — intervention group
Group type: COMPARATOR
Intervention: Paper version of the EORTC QLQ-C30
Number of subjects: 0
Study 22244743 — intervention group
Group type: EXPERIMENTAL
Intervention: bevacizumab-CP
Number of subjects: 180
Study 22244743 — intervention group
Group type: COMPARATOR
Intervention: CP alone
Number of subjects: 180
Study 19173747 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise rehabilitation program informed by a participant preferences questionnaire
Number of subjects: 150
Study 19173747 — intervention group
Group type: COMPARATOR
Intervention: Usual exercise prescription (without preferences questionnaire)
Number of subjects: 150
Study 17929306 — intervention group
Group type: EXPERIMENTAL
Intervention: CPG 10101 at 0.75 mg/kg SC once weekly for 4 weeks
Number of subjects: 60
Study 17929306 — intervention group
Group type: EXPERIMENTAL
Intervention: CPG 10101 (doses >/= 1 mg)
Number of subjects: 60
Study 17929306 — intervention group
Group type: EXPERIMENTAL
Intervention: CPG 10101
Number of subjects: 60
Study 17929306 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 15178658 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical dilatation before embryo transfer
Number of subjects: 283
Study 15178658 — intervention group
Group type: COMPARATOR
Intervention: No cervical dilatation
Number of subjects: 283
Study 12492614 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin/clavulanic acid (75 mg kg‐1 day‐1, 25 mg kg‐1 every 8 h)
Number of subjects: 203
Study 12492614 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 203
Study 9816718 — intervention group
Group type: EXPERIMENTAL
Intervention: ondansetron 0.1 mg/kg
Number of subjects: 80
Study 9816718 — intervention group
Group type: COMPARATOR
Intervention: saline placebo
Number of subjects: 80
Study 8867566 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine + Captopril
Number of subjects: 368
Study 8867566 — intervention group
Group type: COMPARATOR
Intervention: Methyldopa
Number of subjects: 368
Study 8867566 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 368
Study 8867566 — intervention group
Group type: COMPARATOR
Intervention: Normotensives
Number of subjects: 368
Study 2572184 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid bolus injection of vecuronium bromide (0.015 mg/kg)
Number of subjects: 0
Study 2572184 — intervention group
Group type: COMPARATOR
Intervention: Slow infusion of vecuronium bromide (0.015 mg/kg) over 5 min
Number of subjects: 0
Study 52050 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase and plasminogen infusion
Number of subjects: 17
Study 52050 — intervention group
Group type: COMPARATOR
Intervention: Streptokinase infusion only (Control)
Number of subjects: 17
Study 31039826 — intervention group
Group type: EXPERIMENTAL
Intervention: Spermidine supplementation for 12 months
Number of subjects: 100
Study 31039826 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 months
Number of subjects: 100
Study 28532439 — intervention group
Group type: EXPERIMENTAL
Intervention: Oncokompas eHealth self-management application
Number of subjects: 544
Study 28532439 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (wait-list control group)
Number of subjects: 544
Study 25200983 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual brushing (G1)
Number of subjects: 40
Study 25200983 — intervention group
Group type: EXPERIMENTAL
Intervention: Electric toothbrush on (G2)
Number of subjects: 40
Study 25200983 — intervention group
Group type: COMPARATOR
Intervention: Electric toothbrush off (G3)
Number of subjects: 40
Study 25200983 — intervention group
Group type: COMPARATOR
Intervention: Comparison between G1 and G3
Number of subjects: 40
Study 25200983 — intervention group
Group type: COMPARATOR
Intervention: Comparison between G2 and G3
Number of subjects: 40
Study 25200983 — intervention group
Group type: COMPARATOR
Intervention: Comparison between G1 and G2
Number of subjects: 40
Study 23701274 — intervention group
Group type: EXPERIMENTAL
Intervention: Benfotiamine (900 mg/day for 6 weeks)
Number of subjects: 31
Study 23701274 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 22178840 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser treatment
Number of subjects: 17
Study 22178840 — intervention group
Group type: COMPARATOR
Intervention: Ultrasonic subgingival scaling and root planing with hand instrument (SRP)
Number of subjects: 17
Study 22178840 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser treatment for sites with PD≥4 mm
Number of subjects: 17
Study 22178840 — intervention group
Group type: COMPARATOR
Intervention: Conventional SRP for sites with PD≥4 mm
Number of subjects: 17
Study 18851769 — intervention group
Group type: EXPERIMENTAL
Intervention: Theory of Planned Behaviour (TPB) intervention targeting subjective norms through an interactive educational intervention
Number of subjects: 0
Study 18851769 — intervention group
Group type: COMPARATOR
Intervention: Control site (no specific intervention mentioned)
Number of subjects: 0
Study 16252275 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditional Markov model with non-ignorable dropout component
Number of subjects: 0
Study 16252275 — intervention group
Group type: EXPERIMENTAL
Intervention: Applications to a data set from a parasitic field infection survey
Number of subjects: 0
Study 16252275 — intervention group
Group type: EXPERIMENTAL
Intervention: Applications to a data set from a cocaine treatment study
Number of subjects: 0
Study 16252275 — intervention group
Group type: EXPERIMENTAL
Intervention: Applications to a data set from an aging study
Number of subjects: 0
Study 15209771 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled insulin (60, 90, 120, 150 U)
Number of subjects: 13
Study 15209771 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous (s.c.) injected regular human insulin (8, 14, or 20 U)
Number of subjects: 13
Study 11424544 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg ginseng
Number of subjects: 83
Study 11424544 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg ginseng
Number of subjects: 83
Study 11424544 — intervention group
Group type: COMPARATOR
Intervention: Placebo (lactose)
Number of subjects: 83
Study 9421749 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactions with deviant child confederates (ADHD, CD, ODD)
Number of subjects: 60
Study 9421749 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to deviant child confederates
Number of subjects: 60
Study 9421749 — intervention group
Group type: COMPARATOR
Intervention: Interactions with normal child confederates
Number of subjects: 60
Study 8252786 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcipotriol alone
Number of subjects: 48
Study 8252786 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcipotriol plus occlusion
Number of subjects: 48
Study 8252786 — intervention group
Group type: EXPERIMENTAL
Intervention: Occlusion plus calcipotriol
Number of subjects: 48